Table 2 Presenting symptoms and pulmonary function data across the entire cohort (N = 51) and the women-only cohort (N = 40)

Presenting symptom(s)

 Cough

6 (12)

5 (13)

 Cough and dyspnea

7 (14)

6 (15)

 Wheezing

1 (2)

1 (3)

 Hemoptysis

1 (2)

1 (3)

 Dyspnea

11 (22)

10 (25)

 Post-transplant surveillance

4 (8)

2 (5)

 Incidental CT findings

21 (41)

15 (38)

Duration of respiratory symptoms, months

 Median [IQR]

16 [4–72]

19 [4–72]

Pulmonary function testing^¥

PFT pattern

N = 39

N = 33

 Normal

12 (31)

11 (33)

 Obstructive

10 (26)

9 (27)

 Restrictive

11 (28)

7 (21)

 Mixed

0 (0)

0 (0)

 Nonspecific

6 (15)

6 (18)

Severity of respiratory impairment^¶

N = 27

N = 22

 ≥ 70% predicted

11 (41)

8 (36)

 60–69% predicted

8 (30)

7 (32)

 50–59% predicted

3 (11)

3 (14)

 35–49% predicted

3 (11)

2 (9)

 < 35% predicted

2 (7)

2 (9)

Air trapping and hyperinflation

 Patients with lung volume measurements

N = 31

N = 26

 Air trapping present

10 (32)

9 (35)

 Hyperinflation present

3 (10)

3 (12)

Diffusing capacity

 Patients with lung volume measurements

N = 31

N = 26

 DLCO reduced

15 (48)

12 (46)

 Degree of DLCO reduction (% predicted); median [IQR]

51 [48–61]

50 [45–61]

 Bronchodilator responsiveness

 Patients with BD responsiveness testing

N = 26

N = 22

 Positive BD response

5 (19)

5 (23)

 Negative BD response

21 (81)

17 (77)